- Home
- STTK vs FBIO Comparison
STTK vs FBIO Comparison
Compare STTK & FBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- STTK
- FBIO
- Stock Information
- Founded
- STTK 2016
- FBIO 2006
- Country
- STTK United States
- FBIO United States
- Employees
- STTK N/A
- FBIO N/A
- Industry
- STTK Biotechnology: Pharmaceutical Preparations
- FBIO Biotechnology: Pharmaceutical Preparations
- Sector
- STTK Health Care
- FBIO Health Care
- Exchange
- STTK Nasdaq
- FBIO Nasdaq
- Market Cap
- STTK 83.8M
- FBIO 88.7M
- IPO Year
- STTK 2020
- FBIO N/A
- Fundamental
- Price
- STTK $2.14
- FBIO $3.43
- Analyst Decision
- STTK Hold
- FBIO Strong Buy
- Analyst Count
- STTK 6
- FBIO 2
- Target Price
- STTK $2.67
- FBIO $16.50
- AVG Volume (30 Days)
- STTK 1.5M
- FBIO 1.3M
- Earning Date
- STTK 11-13-2025
- FBIO 11-13-2025
- Dividend Yield
- STTK N/A
- FBIO N/A
- EPS Growth
- STTK N/A
- FBIO N/A
- EPS
- STTK N/A
- FBIO N/A
- Revenue
- STTK $2,997,000.00
- FBIO $59,301,000.00
- Revenue This Year
- STTK N/A
- FBIO $51.59
- Revenue Next Year
- STTK N/A
- FBIO $44.74
- P/E Ratio
- STTK N/A
- FBIO N/A
- Revenue Growth
- STTK N/A
- FBIO N/A
- 52 Week Low
- STTK $0.69
- FBIO $1.33
- 52 Week High
- STTK $3.95
- FBIO $3.97
- Technical
- Relative Strength Index (RSI)
- STTK 58.93
- FBIO 63.91
- Support Level
- STTK N/A
- FBIO $3.26
- Resistance Level
- STTK $2.01
- FBIO $3.97
- Average True Range (ATR)
- STTK 0.21
- FBIO 0.31
- MACD
- STTK 0.01
- FBIO 0.05
- Stochastic Oscillator
- STTK 99.53
- FBIO 67.66
About STTK Shattuck Labs Inc.
Shattuck Labs Inc is a biotechnology company specializing in the development of potential treatments for inflammatory and immune-mediated diseases. It is developing a potentially first-in-class antibody for the treatment of inflammatory bowel disease (IBD) and other inflammatory and immune-mediated diseases. The company's expertise in protein engineering and the development of novel tumor necrosis factor (TNF) receptor therapeutics comes together in its main program, SL-325, which has the potential to be a first-in-class death receptor 3 (DR3) antagonist antibody. In addition, the company is developing SL-425, a half-life extended version of SL-325, and multiple other preclinical DR3-based bispecific antibodies, for the treatment of patients with IBD.
About FBIO Fortress Biotech Inc.
Fortress Biotech Inc is a biopharmaceutical company. The firm is involved in the business of acquiring, developing, and commercializing pharmaceutical and biotechnology products. Its product portfolio encompasses Qbrexza, Accutane, Amzeeq, Zilxi, Targadox, Ximino, and Exelderm. The business activities of the group are functioned through Dermatology Product Sales, and Pharmaceutical and Biotechnology Product Development. It derives the majority of its revenues from Dermatology segment. Its subsidiaries also operate in biotechnology, pharmaceutical, oncology and therapeutics sectors.